Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair
VIR sits 88% above its 52-week low of $4.155.
Summary
Vir Biotechnology appointed Timothy Coughlin, a CPA, to its Board of Directors and as Chair of the Audit Committee, enhancing financial oversight.
Key Events · Executive and Board Changes · VIR
-
Board Expansion
The Board of Directors increased its size from seven to eight members.
-
New Director Appointment
Timothy Coughlin, a CPA, was appointed as a Class III director, effective immediately, to serve until the 2028 annual meeting.
-
Audit Committee Chair
Mr. Coughlin was also appointed as Chair of the Audit Committee of the Board.
-
Compensation Details
As a non-employee director, Mr. Coughlin will receive standard cash and equity compensation, including stock option and restricted stock unit awards.
Analysis · VIR · Life Sciences
Vir Biotechnology has expanded its Board of Directors and appointed Timothy Coughlin, a CPA, to fill the new vacancy and chair the Audit Committee. This move strengthens the company's corporate governance and financial oversight, bringing additional expertise to a critical board function.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VIR was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.16 to $11.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.